As a key partner, we are proud to announce that PragmaTIL has received regulatory approval to launch its clinical trial, bringing safer and more effective cell therapy one step closer to cancer patients.

🔬 The trial will start at VHIO (Spain) and Herlev Hospital (Denmark), with approval for NKI (Netherlands) expected soon. Each center will independently produce Tumor-Infiltrating Lymphocytes (TIL) under unified standards.

👥 Patient involvement is at the heart of PragmaTIL. A Patient Advisory Committee helped shape the trial from the start, ensuring patient insights were integrated into the protocol. Key study outcomes—toxicity and quality of life (QoL)—were co-selected with patients to reflect what truly matters.

🎯 The goal? To optimize TIL-ACT therapy, reducing toxicity while maintaining efficacy for patients with melanoma, lung cancer, and cervical cancer.

Learn more: www.pragmatil.eu/news

🇪🇺 Funded by the EU #HorizonEU research and innovation programme.